CELU – celularity inc. - class a (US:NASDAQ)
Stock Stats
News
Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease
Michel Dard of BioCellgraft Wins Business Worldwide Magazines 2025 CEO Award [Yahoo! Finance]
Celularity (NASDAQ:CELU) was upgraded by analysts at WBB Securities from a "hold" rating to a "buy" rating. They now have a $6.00 price target on the stock.
Form 4 Celularity Inc For: Nov 19 Filed by: Parks Diane L.
Form 4 Celularity Inc For: Nov 19 Filed by: LeVien Vincent
Form 4 Celularity Inc For: Nov 19 Filed by: Ling Geoffrey M.D.
Form 4 Celularity Inc For: Nov 19 Filed by: Diamandis Peter
Form 10-Q Celularity Inc For: Sep 30
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.